EIKN
Eikon Therapeutics, Inc.
Price Chart
Latest Quote
$10.88
+0.42 (+4.02%)
Current Price
| Previous Close | $10.46 |
| Open | $10.35 |
| Day High | $10.94 |
| Day Low | $10.10 |
| Volume | 333,491 |
Stock Information
| Shares Outstanding | 54.17M |
| Total Debt | $252.22M |
| Cash Equivalents | $531.18M |
| Net Income | $-322.16M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $589.32M |
| EPS (TTM) | $-6.17 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $310.36M |
| Income | $-322.16M |
| Book/sh | $8.62 |
| Cash/sh | $9.81 |
| Employees | 384 |
Financial Ratios
| Quick Ratio | 9.61 |
| Current Ratio | 9.89 |
| Debt/Eq | 54.07 |
Returns & Margins
Ownership
| Insider Ownership | 17.38% |
| Institutional Ownership | 69.19% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -1.72 |
| P/B | 1.26 |
Analyst Data
| Recommendation | buy |
| Target Price | $24.60 |
Technical Indicators
| SMA20 | $10.71 |
| SMA50 | $10.50 |
| RSI | 53.55 |
| ATR | 1.2093 |
| Shares Float | 29.87M |
| Short Float | 10.25% |
| Short Ratio | 12.79 |
| Rel Volume | 0.67 |
Performance History
| Week | -2.51% |
| Month | +18.13% |
| Quarter | +0.83% |
| 6 Months | -26.88% |
| YTD | -27.47% |
| 10 Years | -27.47% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-09-01 | $10.88 | 333,500 |
| 2026-08-31 | $10.46 | 290,700 |
| 2026-08-27 | $11.52 | 261,700 |
| 2026-08-26 | $11.98 | 324,100 |
| 2026-08-25 | $12.55 | 567,200 |
| 2026-08-24 | $11.16 | 398,300 |
| 2026-08-21 | $11.39 | 532,800 |
| 2026-08-20 | $10.75 | 559,700 |
| 2026-08-19 | $12.01 | 1,406,700 |
| 2026-08-18 | $11.65 | 747,800 |
| 2026-08-17 | $10.47 | 415,000 |
| 2026-08-14 | $11.05 | 637,700 |
| 2026-08-13 | $10.33 | 370,300 |
| 2026-08-12 | $10.42 | 371,300 |
| 2026-08-11 | $10.23 | 502,400 |
| 2026-08-10 | $9.73 | 504,700 |
| 2026-08-07 | $9.29 | 662,400 |
| 2026-08-06 | $9.21 | 361,600 |
| 2026-08-05 | $9.55 | 277,000 |
| 2026-08-04 | $9.56 | 395,900 |
| 2026-08-03 | $9.15 | 256,700 |
About Eikon Therapeutics, Inc.
Eikon Therapeutics, Inc., operates as a clinical biopharmaceutical company in the United States. It develops medicines to address serious unmet medical needs. Its products include EIK1001, a systemically administered TLR 7/8 dual-agonist designed to activate innate and adaptive immune anti-tumor responses; EIK1003 and EIK1004, which are selective PARP1 inhibitors in ovarian, breast, prostate, and pancreatic cancers and, specifically with the brain-penetrant; EIK1004 to address brain metastases and primary brain malignancies; EIK1005, a potent WRN helicase inhibitor and anti-tumor agent for MSI-high tumors; and EIK1006, a clinical candidate and next-generation androgen receptor antagonist with activity against multiple clinically emergent variants of androgen receptor. The company was incorporated in 2019 and is based in Millbrae, California.
đ° Latest News
Eikon Therapeutics Eyes Safer PARP1 Cancer Treatments With EIK1003, EIK1004
MarketBeat âĸ 2026-08-22T11:01:56Z
Is Eikon Therapeutics, Inc. (EIKN) Stock a Biotech Growth Opportunity Despite Limited Q1 Updates?
Insider Monkey âĸ 2026-07-02T20:06:39Z
Spotify upgraded, First Solar downgraded: Wall Street's top analyst calls
The Fly âĸ 2026-02-26T14:42:06Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenue | |||
| Total Revenue | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 |
| Expenses | |||
| Interest Expense | $837,000 | $31,000 | $39,000 |
| Total Expenses | $338,945,000 | $260,343,000 | $265,737,000 |
| Other Income Expense | $-32,000 | $-3,000 | $42,000 |
| Other Non Operating Income Expenses | $-32,000 | $-3,000 | $42,000 |
| Net Non Operating Interest Income Expense | $14,729,000 | $16,532,000 | $23,698,000 |
| Interest Expense Non Operating | $837,000 | $31,000 | $39,000 |
| Operating Expense | $338,945,000 | $260,343,000 | $265,737,000 |
| General And Administrative Expense | $88,627,000 | $55,807,000 | $58,476,000 |
| Income & Earnings | |||
| Net Income From Continuing Operation Net Minority Interest | $-324,248,000 | $-243,814,000 | $-241,997,000 |
| Net Interest Income | $14,729,000 | $16,532,000 | $23,698,000 |
| Interest Income | $15,566,000 | $16,563,000 | $23,737,000 |
| Normalized Income | $-324,248,000 | $-243,814,000 | $-241,997,000 |
| Net Income From Continuing And Discontinued Operation | $-324,248,000 | $-243,814,000 | $-241,997,000 |
| Total Operating Income As Reported | $-338,945,000 | $-260,343,000 | $-265,737,000 |
| Net Income Common Stockholders | $-333,644,000 | $-243,814,000 | $-241,997,000 |
| Net Income | $-324,248,000 | $-243,814,000 | $-241,997,000 |
| Net Income Including Noncontrolling Interests | $-324,248,000 | $-243,814,000 | $-241,997,000 |
| Net Income Continuous Operations | $-324,248,000 | $-243,814,000 | $-241,997,000 |
| Pretax Income | $-324,248,000 | $-243,814,000 | $-241,997,000 |
| Interest Income Non Operating | $15,566,000 | $16,563,000 | $23,737,000 |
| Operating Income | $-338,945,000 | $-260,343,000 | $-265,737,000 |
| Per Share | |||
| Diluted EPS | $-6.18 | $-7.45 | $-7.40 |
| Basic EPS | $-6.18 | $-7.45 | $-7.40 |
| Other | |||
| Tax Effect Of Unusual Items | $0 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-299,235,000 | $-218,391,000 | $-224,210,000 |
| Reconciled Depreciation | $24,176,000 | $25,392,000 | $17,748,000 |
| EBITDA (Bullshit earnings) | $-299,235,000 | $-218,391,000 | $-224,210,000 |
| EBIT | $-323,411,000 | $-243,783,000 | $-241,958,000 |
| Diluted Average Shares | $53,984,337 | $32,707,651 | $32,707,651 |
| Basic Average Shares | $53,984,337 | $32,707,651 | $32,707,651 |
| Diluted NI Availto Com Stockholders | $-333,644,000 | $-243,814,000 | $-241,997,000 |
| Otherunder Preferred Stock Dividend | $9,396,000 | $0 | - |
| Research And Development | $250,318,000 | $204,536,000 | $207,261,000 |
| Selling General And Administration | $88,627,000 | $55,807,000 | $58,476,000 |
| Other Gand A | $88,627,000 | $55,807,000 | $58,476,000 |
Fetched: 2026-08-25
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Assets | |||
| Net Tangible Assets | $-879,034,000 | $-571,930,000 | $-341,373,000 |
| Total Assets | $594,734,000 | $491,240,000 | $525,705,000 |
| Total Non Current Assets | $245,817,000 | $263,351,000 | $89,279,000 |
| Other Non Current Assets | $8,354,000 | $4,219,000 | $2,399,000 |
| Non Current Deferred Assets | $3,600,000 | - | - |
| Current Assets | $348,917,000 | $227,889,000 | $436,425,000 |
| Other Current Assets | $12,542,000 | $7,378,000 | $6,012,000 |
| Restricted Cash | $400,000 | $400,000 | $0 |
| Cash Cash Equivalents And Short Term Investments | $335,975,000 | $220,111,000 | $430,413,000 |
| Cash And Cash Equivalents | $104,901,000 | $129,179,000 | $112,784,000 |
| Cash Equivalents | $84,960,000 | $15,813,000 | $104,265,000 |
| Cash Financial | $19,941,000 | $113,366,000 | $8,519,000 |
| Debt | |||
| Total Debt | $257,319,000 | $202,459,000 | $31,735,000 |
| Long Term Debt And Capital Lease Obligation | $247,291,000 | $193,152,000 | $26,687,000 |
| Current Debt And Capital Lease Obligation | $10,028,000 | $9,307,000 | $5,048,000 |
| Liabilities | |||
| Total Liabilities Net Minority Interest | $1,473,768,000 | $1,063,170,000 | $867,078,000 |
| Total Non Current Liabilities Net Minority Interest | $1,418,761,000 | $1,006,721,000 | $835,638,000 |
| Other Non Current Liabilities | $10,000,000 | $5,348,000 | $730,000 |
| Current Liabilities | $55,007,000 | $56,449,000 | $31,440,000 |
| Other Current Liabilities | $35,000 | $301,000 | $591,000 |
| Payables And Accrued Expenses | $44,944,000 | $46,841,000 | $25,801,000 |
| Payables | $681,000 | $17,578,000 | $2,187,000 |
| Accounts Payable | $681,000 | $17,578,000 | $2,187,000 |
| Equity | |||
| Common Stock Equity | $-879,034,000 | $-571,930,000 | $-341,373,000 |
| Total Equity Gross Minority Interest | $-879,034,000 | $-571,930,000 | $-341,373,000 |
| Stockholders Equity | $-879,034,000 | $-571,930,000 | $-341,373,000 |
| Retained Earnings | $-920,509,000 | $-604,941,000 | $-361,127,000 |
| Preferred Securities Outside Stock Equity | $1,161,470,000 | $808,221,000 | $808,221,000 |
| Other | |||
| Ordinary Shares Number | $53,984,337 | $53,984,337 | $53,984,337 |
| Share Issued | $53,984,337 | $53,984,337 | $53,984,337 |
| Tangible Book Value | $-879,034,000 | $-571,930,000 | $-341,373,000 |
| Invested Capital | $-879,034,000 | $-571,930,000 | $-341,373,000 |
| Working Capital | $293,910,000 | $171,440,000 | $404,985,000 |
| Capital Lease Obligations | $257,319,000 | $202,459,000 | $31,735,000 |
| Total Capitalization | $-879,034,000 | $-571,930,000 | $-341,373,000 |
| Additional Paid In Capital | $41,475,000 | $33,011,000 | $19,754,000 |
| Capital Stock | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 |
| Long Term Capital Lease Obligation | $247,291,000 | $193,152,000 | $26,687,000 |
| Current Capital Lease Obligation | $10,028,000 | $9,307,000 | $5,048,000 |
| Current Accrued Expenses | $44,263,000 | $29,263,000 | $23,614,000 |
| Net PPE | $233,863,000 | $259,132,000 | $86,880,000 |
| Accumulated Depreciation | $-42,914,000 | $-33,902,000 | $-18,895,000 |
| Gross PPE | $276,777,000 | $293,034,000 | $105,775,000 |
| Leases | $120,588,000 | $18,613,000 | $18,337,000 |
| Construction In Progress | $624,000 | $96,858,000 | $5,416,000 |
| Other Properties | $131,717,000 | $158,281,000 | $67,081,000 |
| Machinery Furniture Equipment | $23,848,000 | $19,282,000 | $14,941,000 |
| Properties | $0 | $0 | $0 |
| Other Short Term Investments | $231,074,000 | $90,932,000 | $317,629,000 |
Fetched: 2026-08-25
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Free Cash Flow | |||
| Free Cash Flow | $-235,257,000 | $-219,602,000 | $-219,361,000 |
| Operating Activities | |||
| Operating Cash Flow | $-188,516,000 | $-134,799,000 | $-190,848,000 |
| Cash Flow From Continuing Operating Activities | $-188,516,000 | $-134,799,000 | $-190,848,000 |
| Investing Activities | |||
| Capital Expenditure | $-46,741,000 | $-84,803,000 | $-28,513,000 |
| Investing Cash Flow | $-181,343,000 | $151,350,000 | $136,950,000 |
| Cash Flow From Continuing Investing Activities | $-181,343,000 | $151,350,000 | $136,950,000 |
| Financing Activities | |||
| Issuance Of Capital Stock | $352,053,000 | $244,000 | $105,812,000 |
| Financing Cash Flow | $352,053,000 | $244,000 | $105,812,000 |
| Cash Flow From Continuing Financing Activities | $352,053,000 | $244,000 | $105,812,000 |
| Net Preferred Stock Issuance | $350,153,000 | $0 | $105,410,000 |
| Preferred Stock Issuance | $350,153,000 | $0 | $105,410,000 |
| Net Common Stock Issuance | $1,900,000 | $244,000 | $402,000 |
| Common Stock Issuance | $1,900,000 | $244,000 | $402,000 |
| Other | |||
| Interest Paid Supplemental Data | $889,000 | $31,000 | $39,000 |
| End Cash Position | $113,072,000 | $130,878,000 | $114,083,000 |
| Beginning Cash Position | $130,878,000 | $114,083,000 | $62,169,000 |
| Changes In Cash | $-17,806,000 | $16,795,000 | $51,914,000 |
| Net Investment Purchase And Sale | $-134,602,000 | $236,153,000 | $165,463,000 |
| Sale Of Investment | $309,500,000 | $596,500,000 | $970,200,000 |
| Purchase Of Investment | $-444,102,000 | $-360,347,000 | $-804,737,000 |
| Net PPE Purchase And Sale | $-46,741,000 | $-84,803,000 | $-28,513,000 |
| Purchase Of PPE | $-46,741,000 | $-84,803,000 | $-28,513,000 |
| Change In Working Capital | $77,835,000 | $80,650,000 | $9,976,000 |
| Change In Other Current Liabilities | $71,459,000 | $75,721,000 | $-6,792,000 |
| Change In Other Current Assets | $-1,263,000 | $-1,820,000 | $1,268,000 |
| Change In Payables And Accrued Expense | $12,803,000 | $8,115,000 | $17,330,000 |
| Change In Accrued Expense | $16,616,000 | $5,164,000 | $17,091,000 |
| Change In Payable | $-3,813,000 | $2,951,000 | $239,000 |
| Change In Account Payable | $-3,813,000 | $2,951,000 | $239,000 |
| Change In Prepaid Assets | $-5,164,000 | $-1,366,000 | $-1,830,000 |
| Other Non Cash Items | $-5,541,000 | $-9,456,000 | $13,887,000 |
| Stock Based Compensation | $18,036,000 | $12,429,000 | $9,538,000 |
| Asset Impairment Charge | $21,226,000 | $0 | - |
| Depreciation Amortization Depletion | $24,176,000 | $25,392,000 | $17,748,000 |
| Depreciation And Amortization | $24,176,000 | $25,392,000 | $17,748,000 |
| Depreciation | $24,176,000 | $25,392,000 | $17,748,000 |
| Net Income From Continuing Operations | $-324,248,000 | $-243,814,000 | $-241,997,000 |
Fetched: 2026-08-25